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THE DEVELOPMENT OF NOVEL THERAPEUTICS FOR 
SICKLE-CELL DISEASE 
Sara Costello, Steven SturHs and Brian Brennan* 
Chemistry Department, Illinois Wesleyan University 
Sickle-cell disease has been widely studied since the disorder was first described early in the 20th 
century. It is caused by a mutation in the gene coding for adult hemoglobin which leads to 
protein aggregation. The aggregated protein changes the shape of red blood cells and causes 
severe pain, fatigue and organ damage in afflicted individuals. Despite the fact that the molecular 
basis for sickle cell disease was first discovered in 1957 and its molecular mechanism has been 
described in detail, no effective treatment has thus been discovered. 
As a novel approach to treating this ailment, our research focuses on the discovery of molecules 
that can bind to sickle-cell hemoglobin and disrupt protein polymerization. Our initial studies 
have focused on peptides and peptidomimetics (oligomers which mimic peptides) due to their 
great diversity and ease of synthesis through solid phase techniques. In fact, others have recently 
shown small peptides derived from hemoglobin are capable of disrupting the interaction. Using a 
combination of rational design and screening approaches, we hope to discover new therapeutic 
agents and help treat this devastating disease. 
